Lv3
204 积分 2023-01-29 加入
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
1个月前
已完结
Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy
1个月前
已完结
A model for RAS mutation patterns in cancers: finding the sweet spot
1个月前
已完结
Tertiary lymphoid structures in cancer
5个月前
已完结
Intratumoral Injection of R848 and Poly(I:C) Synergistically Promoted Antitumour Immune Responses by Reprogramming Macrophage Polarization and Activating DCs in Lung Cancer
5个月前
已完结
Molecular glue meets antibody: next-generation antibody–drug conjugates
5个月前
已完结
CDK inhibitors from past to present: A new wave of cancer therapy
5个月前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
5个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
5个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
5个月前
已完结
皖公网安备34019202002308